Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ5APT)

Drug Name
QBW251 Drug Info
Synonyms
Icenticaftor; 1334546-77-8; Qbw251; Icenticaftor [INN]; Icenticaftor [USAN]; AMB0BO0WFH; QBW-251; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; (S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; UNII-AMB0BO0WFH; Icenticaftor [USAN:INN]; SCHEMBL2372751; CHEMBL4650318; GTPL11547; US10117858, Example 5; BDBM297402; DTXSID601336884; WHO 11246; AKOS040759841; compound 33 [PMID: 34028270]; MS-25717; HY-109177; CS-0116371; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Cross-matching ID
PubChem CID
58442344
TTD Drug ID
DMQ5APT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting cAMP-dependent chloride channel (CFTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [3]
Crofelemer DM4AMQZ HIV-associated diarrhoea 1A2Z Approved [4]
Tezacaftor and ivacaftor DMY62FC Acute lung injury NB32.3 Approved [5]
VX-661 DMJBXO3 Cystic fibrosis CA25 Phase 3 [6]
ABBV-2222 DM4ZLTY Cystic fibrosis CA25 Phase 2 [7]
GLPG-1837 DMOCRYB Cystic fibrosis CA25 Phase 2 [7]
iOWH032 DM5TMYC Diarrhea ME05.1 Phase 2 [8]
Lumacaftor DMCLWDJ Cystic fibrosis CA25 Phase 2 [9]
ABBV-3067 DMB01L5 Cystic fibrosis CA25 Phase 1 [7]
ABBV-2737 DMU6K37 Cystic fibrosis CA25 Phase 1 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
cAMP-dependent chloride channel (CFTR) TTRLZHP CFTR_HUMAN Potentiator [2]

References

1 ClinicalTrials.gov (NCT04268823) A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
2 Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
7 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
8 Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
9 A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.